HALO Halozyme Therapeutics, Inc.

NASDAQ
$96.50

Halozyme Therapeutics, Inc. (HALO) Earnings News

Earnings press releases, previews and reviews for Halozyme Therapeutics, Inc. (HALO), newest first. Our most recent is review: Halozyme Posts Record Royalties, a Third Guidance Raise and a European Win Against Merck, but the Raise Is Smaller and Growth Is Cooling.